MedTrace Logo

Study of the Use of the Ingaron in Volunteers for the Prevention of COVID-19

NCT05386446 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-05-23

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the effectiveness of the prophylactic use of Ingaron (INN: recombinant interferon gamma human, lyophilisate for solution for intranasal administration 100,000 IU) in the regimen of 3 drops in each nasal passage intranasally every other day for 10 days with a break of 7 days (2 10-day cycles) in volunteers.

Conditions

  • COVID-19 Respiratory Infection

Interventions

DRUG

Interferon gamma human recombinant (IFN-G)

nasal form

Sponsors & Collaborators

  • SPP Pharmaclon Ltd.

    lead INDUSTRY

Principal Investigators

  • Anatoly I Saulin, Master · SPP Pharmaclon Ltd.

Eligibility

Min Age
21 Years
Max Age
62 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-23
Primary Completion
2020-06-10
Completion
2020-06-15

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05386446 on ClinicalTrials.gov